- Global Pharma News & Resources

Chemotherapy Dominates Treatment Options in Fibrosarcoma Industry

Fibrosarcoma is a type of malignant cancer, which is associated with fibrous connective tissue, and the ailment primarily results in the proliferation of fibroblasts along with anaplastic variants of spindle cells, which form in a storiform pattern. The condition is most commonly found in males aged between 30 and 40 years.

The global fibrosarcoma market is projected to grow at a steady CAGR of ~ 5.5 per cent through the end of the forecast period in 2026. This growth is projected to account for a revenue value of USD 442.4 million by the end of 2026. The rise of the industry to develop treatments for fibrosarcoma is attributed to the wider prevalence of targeted treatments for cancer.

The industry is further supported through the advancements in terms of chemotherapy and radiotherapy. On the other hand, radiotherapy for cancer treatments can also lead to fibrosarcoma. Consequently, researchers are increasingly focusing on the development of therapies which target unhealthy cells.

Request Sample Report-

Major pharmaceutical companies are also increasingly investing in the research and development activities, which are effective for the treatment of different types of sarcomas, including fibrosarcoma.

Hospitals to Gain in Terms of Major Revenue Share

Hospitals are expected to be major gainers from the fibrosarcoma market during the entire forecast period, up to 2026. This growth will account for around two-fifths of the overall revenue share in the industry. This growth for hospitals is also expected to result in an incremental opportunity of approximately 100 million USD, owing to monetary support by governments, and contributions for healthcare infrastructure for the growth of hospitals for technologically advanced treatments.

Further, Hospital pharmacies are set to become some of the largest channels of distribution for medications in the global fibrosarcoma market. This revenue rise will account for ~ USD 200 million by the end of 2026.

In many countries, the distribution of drugs for cancer treatments will come from hospital pharmacies. In addition, government support and the availability of drugs will result in the rise of hospital pharmacies as a primary channel of distribution.

Read Report Overview-

Chemotherapy Continues as Dominant Treatment Option

While fibrosarcoma can be treated with various options, including surgery, radiation therapy and others, chemotherapy is expected to become the preferred option among health care professionals, owing to its higher rates of success, particularly in cases where despite the cancer being large, spread has not started.

Such treatments allow for reduction in fibrosarcoma and also aids in cutting down the need for most surgery. As a result the value of the chemotherapy treatments is expected to surpass USD 100 million during the forecast period.

Further, correct diagnosis is considered to be vital before treatments are initiated. Most fibrosarcoma cases have to go through multiple referrals, owing to the rarity of malignant tumors of the bone. Such referrals also allow the patient access to the services of such rare conditions, including reviews from surgical oncologists, medical oncologists, pathologist, radiation oncologist, pediatric oncologists, and radiologists, which has become a standard of care for fibrosarcoma.

Request Research Methodology-

About Fact.MR

Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that’s why we publish multi-industry global, regional, and country-specific research reports.

Contact Us


11140 Rockville Pike

Suite 400

Rockville, MD 20852

United States




Editor Details

Last Updated: 14-Jan-2020